FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/05/2024
Back to search
Official data from USPTO
ARCERIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
02/05/2024
Trademark type
Combined
Nice classes
5
Filing date
01/28/2022
Registration date
10/10/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/10/2023
Last transaction
10/10/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
16
Owner location
RU
Examiner
PARKS, KIMBERLY L
Law office
M30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
R-PHARM INTERNATIONAL, LLC
Representatives
Kumiko Ide Wenderoth, Lind & Ponack, L.L.P.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of familial Mediterranean fever; Pharmaceutical preparations for the treatment of adult-onset Still's disease; Pharmaceutical preparations for the treatment of idiopathic recurrent pericarditis; Pharmaceutical preparations for the treatment of recurrent pericarditis; Pharmaceutical preparations for secondary prevention of major adverse cardiovascular events after ST-elevation myocardial infarction; Pharmaceutical preparations for the treatment of chronic heart failure; Pharmaceutical preparations for the treatment of macrophage activation syndrome; Pharmaceutical preparations for the treatment of systemic juvenile idiopathic arthritis; Pharmaceutical preparations for the treatment of cryopyrin-associated periodic syndromes; Pharmaceutical preparations for the treatment of tumor necrosis factor receptor associated periodic syndrome; Pharmaceutical preparations for the treatment of Schnitzler syndrome; Pharmaceutical preparations for the treatment of acute gout attacks
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/11/2024
FIMP
FINAL DISPOSITION PROCESSED
01/11/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/10/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/10/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
10/10/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/03/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/13/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/13/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/25/2023
PUBO
PUBLISHED FOR OPPOSITION
07/25/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/22/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/06/2023
RFNT
REFUSAL PROCESSED BY IB
02/14/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/24/2023
RFRR
REFUSAL PROCESSED BY MPU
01/24/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/19/2022
CNRT
NON-FINAL ACTION WRITTEN
11/18/2022
DOCK
ASSIGNED TO EXAMINER
11/09/2022
MAFR
APPLICATION FILING RECEIPT MAILED
04/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/08/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/07/2022
Continuous trademark protection
Get notified about every new filing that threatens ARCERIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.